Bariatric surgery

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Commitment, Research, Obesity, PTE, Exercise, Bariatrics, Patent, Patient, Food and Drug Administration, Weight loss, Travel, Acquisition, FLEX, Prescription, NYU, Food, Security (finance), Insurance, Marketing, Surgeon, C-peptide, Annual report, PMA, NYU Langone Health, Division, United States patent law, FDA, Advertising, Bariatric surgery

IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update.

Key Points: 
  • Specifically, it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819.
  • December 2023: Engaged Maxim Group LLC, to act as the company’s exclusive financial advisor to help identify potential synergistic merger and acquisition partnerships.
  • December 2023: Received U.S. Food and Drug Administration (FDA) PMA supplement approval for its next-generation Lap-Band® 2.0 FLEX, designed to improve the patient experience.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.

Global Medical Aesthetics Market, 2023-2035: Dominance of Minimally Invasive Procedures - North America Leads, Asia-Pacific Shows Promise - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Other Consumer, Medical Devices, Surgery, Women, LGBTQ+, Men, Consumer, Health, Cosmetics, Retail, Migraine, Type, Medical tourism, Elective surgery, COVID-19, Bariatric surgery, Hospital, Dermatology, IPL, Ageing, Breast, Cellulite, Safety, Market, Physician, FACE, Practitioner

The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.

Key Points: 
  • The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.
  • Presently, more than 200 medical aesthetics companies are engaged in offering various products and devices to fulfill aesthetic requirements of clients.
  • Additionally, medical aesthetic companies offer all types of invasive, non invasive and minimally invasive solutions to address the requirements of all end users, such as hospitals, medical aesthetic clinic and individuals in home care settings.
  • North America leads the medical aesthetics market, driven by advanced solutions, established companies, and high demand for cosmetic procedures.

Allurion Expands Virtual Care Suite to the United States

Retrieved on: 
Thursday, April 4, 2024
Women, Other Health, Other Technology, Men, Telemedicine, Virtual Medicine, Family, Medical Devices, Hospitals, Consumer, Fitness & Nutrition, Technology, General Health, Biotechnology, Diabetes, Surgery, Health, Apps, Applications, Health Technology, Bariatric surgery, Conference, Obesity, VCS, Patient, Research, Artificial intelligence, Digital health, Digital, NPS, Satellite navigation device

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.

Key Points: 
  • Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.
  • In 2023, Allurion added Coach Iris, a 24/7 AI-powered weight loss coach, to the VCS, enabling automated, conversational coaching and a more personalized behavior change program tailored to patient needs.
  • “After witnessing the profound impact our technology has had globally, we are thrilled to launch the VCS in the United States.
  • As part of the launch, Allurion will also be unveiling a new version of Allurion Insights, the web-based dashboard that providers use to navigate the VCS.

Global Bariatric Surgery Market Analysis Report 2024-2033: Escalating Demand for Weight Loss Interventions, Increasing Awareness and Accessibility, Advancements in Minimally Invasive Techniques - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Surgery, Health, Bariatric surgery, Overweight, Cardiovascular disease, Obesity, Growth, Patient, Weight loss, Competitive landscape, Cancer, Type 2 diabetes, Projection, DSM-IV codes

This comprehensive report provides a detailed analysis of market trends, key players, and growth opportunities within the bariatric surgery sector.

Key Points: 
  • This comprehensive report provides a detailed analysis of market trends, key players, and growth opportunities within the bariatric surgery sector.
  • The expanding market for bariatric surgery is fueled by the escalating demand for weight loss interventions, reflecting the ongoing increase in overweight and obese populations worldwide.
  • Key Questions Answered in this Report:
    What is the size of the global bariatric surgery market at the regional and country levels?
  • What is the economic impact on the global bariatric surgery market, and what is the development trend of the market?

World Obesity Drugs and Delivery Platforms Research Report 2023: Pipeline Analysis, Drug Delivery Innovations, Outlook, Acquisitions, Partnerships, and Funding - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
General Health, Biometrics, Health, Fitness & Nutrition, Pharmaceutical, Obesity, Probiotic, Risk, Mineral, Prognosis, Bariatric surgery, Weight loss, BMI, Vitamin, Body mass index, Clinical trial, Mortality, Nutrient, Developed country, Overalls, Fast food

The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.
  • In this study, the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies are analyzed.
  • The study also provides insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.
  • GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.

Levita® Magnetics Achieves First Deployment of MARS™ Surgical System in a Private Institution

Retrieved on: 
Thursday, April 4, 2024
Bariatric surgery, Patient, Hospital, Prostate, Magnetism, Surgeon, Cleveland Clinic, Bypass surgery, Pain, Cholecystectomy, FDA, Health, Medical imaging

MOUNTAIN VIEW, Calif., April 4, 2024 /PRNewswire/ -- Levita Magnetics, whose mission is to expand patient access to advanced surgical care, today celebrates a key advancement in minimally invasive surgery with the deployment of its MARS surgical system at a North Texas-based hospital. This marks a significant milestone as the first implementation of the MARS system in a private institution, representing a critical development in the global expansion of the technology. This expansion follows Levita's recent international introduction in Chile and its first commercial application in the U.S. at Cleveland Clinic in late 2023.

Key Points: 
  • This marks a significant milestone as the first implementation of the MARS system in a private institution, representing a critical development in the global expansion of the technology.
  • "The introduction of the MARS system in Dallas represents a meaningful and impactful advancement in our surgical capabilities," said Dr. Chad Carlton.
  • The MARS system, an FDA-approved surgical platform, innovatively combines magnetic technology and machinery to minimize incisions, enhance visualization, and streamline laparoscopic surgery.
  • MARS builds on the clinical benefits of the Levita Magnetic Surgical System®, incorporating proprietary Dynamic Magnetic Positioning technology with dual surgeon-controlled arms.

Carium and CareDirections Partner to Launch Post-Acute Stroke Care Solution Developed by Atrium Health Wake Forest Baptist

Retrieved on: 
Tuesday, April 2, 2024
Bariatric surgery, Internal medicine, American Heart Association, Health, Neurology, Communication, COMPASS, Incidence, Patient, Stroke, Hospital, Risk, SDOH, Length of stay, Survivor, AHA, Medicare, CMS, Dementia, Nursing

WINSTON-SALEM, N.C., April 2, 2024 /PRNewswire/ -- CareDirections and Carium are announcing the commercial availability of StrokeCP, a clinically and financially validated digital health platform designed by researchers at Atrium Health Wake Forest Baptist and powered by Carium's award-winning patient engagement and virtual care management solution.

Key Points: 
  • The platform pulls together various tools and interventions proven to support care management for stroke survivors post-discharge, leading to improved quality outcomes and reduced cost of care for health systems.
  • "Changes in healthcare delivery and associated costs have challenged providers and patients to monitor and manage care beyond the clinics.
  • It also follows and communicates with patients on behalf of their care providers in the stroke recovery journey and captures patient outcomes and satisfaction with care.
  • This shows the solution can ensure both clinical excellence and financial return, which is crucial for the health systems," said David McCormick, COO at Carium.

Dr. Jason D. Fraser Appointed Division Chief of Pediatric Surgery at Phoenix Children's

Retrieved on: 
Thursday, March 21, 2024
Editorial, Certification, Kansas City University, Mayo Clinic Arizona, Phoenix Children's Hospital, Patient, Mayo Clinic, Trauma, University, MD, American College, General surgery, Hospital, ACS, Mercy, Bariatric surgery, Dentistry

PHOENIX, March 21, 2024 /PRNewswire/ -- Phoenix Children's today announced Jason D. Fraser, MD, will join the rapidly growing health system as division chief of pediatric surgery beginning in April.

Key Points: 
  • PHOENIX, March 21, 2024 /PRNewswire/ -- Phoenix Children's today announced Jason D. Fraser, MD, will join the rapidly growing health system as division chief of pediatric surgery beginning in April.
  • Phoenix Children's is verified by the American College of Surgeons (ACS) as the only Level 1 Children's Surgery Center in Arizona.
  • As division chief of pediatric surgery, Dr. Fraser will provide strategic direction and administrative leadership for neonatal, pediatric and trauma surgery throughout Phoenix Children's health system, which will include three hospital campuses and three ambulatory surgery centers by the end of 2024.
  • Dr. Fraser joins Phoenix Children's from Children's Mercy in Kansas City, Missouri, where he served as medical director of the Opioid Stewardship Program, director of the Pediatric Surgery Fellowship Program, director of Bariatric Surgery and director of General Surgery Residents.

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

Retrieved on: 
Thursday, February 22, 2024
Division, Bariatric surgery, Weight loss, Growth, Food, Bariatrics, NYU, NYU Langone Health, Patient, FLEX

IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort Worth, TX, and Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of NYU Langone Health’s Weight Management Program and Chief of the Division of Bariatric Surgery, have successfully performed the first surgeries utilizing the company’s next generation, enhanced Lap-Band® 2.0 FLEX.

Key Points: 
  • “The first surgeries utilizing the Lap-Band® 2.0 FLEX mark, not only a seminal moment in the company’s launch of this enhanced product, but also a leap forward in improving the Lap-Band® patient experience,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • “We are excited to begin our initial launch of the Lap-Band® 2.0 FLEX that will ultimately demonstrate the real-world benefits of the new FLEX technology, which acts as a relief valve, to alleviate discomfort from swallowing large pieces of food, eliminating the need for in-office band adjustments.
  • I believe it will improve the patient experience by minimizing the need for manual band adjustments, especially when related to the urgent need to relieve food obstructions.
  • This ability for self-correction makes the Lap-Band® 2.0 FLEX a better long-term weight loss solution for my patients and I look forward to increasing its usage in my practice, going forward.”

GlobalData report highlights staggering $425.5 billion economic costs of obesity and overweight to U.S. Businesses and Employees in 2023

Retrieved on: 
Thursday, February 22, 2024
Professional Services, Health, General Health, Publishing, Women, Communications, Men, Data Analytics, Fitness & Nutrition, Consumer, Human Resources, Well, Ageing, Parity, Doctor of Philosophy, Eli Lilly and Company, Diet, GlobalData, Overweight, Compensation, Economic impact analysis, Absenteeism, Weight loss, Culture, Conditional sentence, Bariatric surgery, Prevalence, Presenteeism, Disability, DSM-IV codes, Head, Corporate services, Disease, Insurance, National Consumers League, Rights, Workforce, National Council, Comment, George Washington University, National Council on Aging, Fast food

Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.

Key Points: 
  • Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.
  • Of the 158 million civilian employees on nonfarm payrolls, 30% (46.9M) are classified as having obesity and 34% (53.8M) have overweight.
  • Costs amounted to $347.5 billion attributed to obesity and $78 billion attributed to overweight.
  • Costs include $146.5 billion in higher medical costs for employees and their dependents, $82.3 billion in higher absenteeism (missed workdays), $160.3 billion in higher presenteeism (reduced productivity due to illness), $31.1 billion in higher disability costs, and $5.2 billion in higher Workers’ Compensation Program costs.